“We are going to be seeing more and more complex procedures in the aortic arch and thoracoabdominal aorta”, Gustavo Oderich (University of Texas Health Science Center, Houston, USA) tells Vascular News ahead of this year’s Charing Cross Symposium (CX; 19–22 April, online). With a focus on the theme of this year’s meeting—controversies—Oderich details his planned presentation and outlines what physicians can expect from the Thoracic Aortic session.
Could you briefly summarise the highlights of your planned presentation for CX 2021?
I will have the chance to share some thoughts on thoracoabdominal endovascular repair without drains. This is considered controversial because we have used drains for many years but we have learned that they are not without problems—we all know about the complications of spinal haematoma and intracranial bleeding. I will be sharing whether we have achieved the expected results from a very large dataset without using drains. This is a hot topic and I look forward to having the chance to discuss it at CX.
Why should physicians attend the CX 2021 Thoracic Aortic session?
Endovascular therapy has been widely accepted as the first-line treatment for thoracic disease and we are now in an era where we are going to be seeing more and more complex procedures in the aortic arch and thoracoabdominal aorta. It will be good to learn what are the new devices that are coming along and to get the chance to hear from expert speakers on pressing issues and what we are doing to improve previous limitations on these repairs.